Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study - Concepedia

Concepedia

Publication | Closed Access

Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study

146

Citations

14

References

2021

Year

Marja Puurunen, Jerry Vockley, Shawn Searle, Stephanie Sacharow, John A. Phillips, William S. Denney, Benjamin D. Goodlett, David A. Wagner, Larry Blankstein, Mary Joan Castillo,

Nature Metabolism

EngineeringMedicineFirst-in-human Phase 1/2ABiotechnologySynthetic BiologyE. Coli NisslePharmacologyAntimicrobial ResistancePharmaceutical BiotechnologyBiomolecular EngineeringDrug Resistance

References

	Year	Citations

Page 1

Page 1